Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tumour lysate particle only vaccine - Orbis Health Solutions

Next Previous
Drug Profile

Tumour lysate particle only vaccine - Orbis Health Solutions

Alternative Names: TLPO vaccine

Latest Information Update: 01 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orbis Health Solutions
  • Developer Cancer Insight; Elios Therapeutics
  • Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Malignant melanoma

Most Recent Events

  • 02 Jul 2025 Elios Therapeutics terminates phase-II clinical trial in Solid tumours (Second-line therapy or greater, Early-stage disease, Late-stage disease, Adjunctive treatment) in USA (Intradermal) due to lack of funding (NCT06175221)
  • 29 Nov 2023 Phase-II clinical trials in Solid tumours (Second-line therapy or greater, Early-stage disease, Late-stage disease, Adjunctive treatment) in USA (Intradermal) (NCT06175221)
  • 30 Mar 2021 Phase-I/II trial is still ongoing for Malignant melanoma (In adults, In the elderly, Late-stage disease, Prevention of relapse) in USA (Parenteral) (NCT02301611)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top